denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: PRIME Education, LLC
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Bispecific Antibody Therapy, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapy sequence, Treatment Considerations, Biological therapies, Immunotherapy, Adverse Events, Monoclonal Antibody Therapy
Hematology Disease Topics & Pathways:
Bispecific Antibody Therapy, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapy sequence, Treatment Considerations, Biological therapies, Immunotherapy, Adverse Events, Monoclonal Antibody Therapy
Friday, December 6, 2024: 7:00 PM-10:00 PM
Room 6DE
(San Diego Convention Center)
Chair:
Scott R. Goldsmith, MD, City of Hope
Disclosures:
Goldsmith: Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees.
Speakers:
M. Sarfraz Nawaz, MD, Hematology Oncology of Indiana
,
Melissa Alsina, MD, Moffitt Cancer Center
and
Binod Dhakal, MBBS, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin
Disclosures:
Nawaz: Pharmacosmos: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees; Janssen US Bispecifics: Membership on an entity's Board of Directors or advisory committees; PHARMASSENTIA: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Gilead Sciences: Membership on an entity's Board of Directors or advisory committees; Janssen Biotech: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Genentech: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Alsina: Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Dhakal: Sanofi: Research Funding; Pfizer: Consultancy, Honoraria, Speakers Bureau; C4 therapeutics: Research Funding; Medical College of Wisconsin: Current Employment; Karyopharm: Honoraria, Speakers Bureau; Carsgen: Research Funding; Acrellx: Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Janssen: Honoraria, Research Funding, Speakers Bureau; Genentech: Consultancy, Honoraria.
Join expert faculty as they take a deep dive into the latest clinical evidence and practical considerations
for treatment of complex cases of patients with multiple myeloma (MM). Informed by real-world data
on challenges regarding selection and sequencing treatment plans and coordinating MM care,
highlighting differences stemming from practice setting. Our panelists will participate in insightful
discussions regarding benefits and risks of different treatment options based on the latest clinical data
and patient characteristics, offering different perspectives and institutional differences, with supportive
slides featuring the current clinical evidence as well as strategies for integrating the best treatments for
individual patients into treatment plans, emphasizing nuances between academic- and community-
based settings. The topics for discussion by the expert faculty panel will be supported by clinical cases
and enhanced by interactive polling questions and live questions submitted by attendees throughout
the presentation. Altogether, this satellite symposium will harness real-world experiences providing MM
care to deepen the impact of the education to enhance treatment selection and care coordination for
the optimal integration of novel therapies in MM across practice settings.
for treatment of complex cases of patients with multiple myeloma (MM). Informed by real-world data
on challenges regarding selection and sequencing treatment plans and coordinating MM care,
highlighting differences stemming from practice setting. Our panelists will participate in insightful
discussions regarding benefits and risks of different treatment options based on the latest clinical data
and patient characteristics, offering different perspectives and institutional differences, with supportive
slides featuring the current clinical evidence as well as strategies for integrating the best treatments for
individual patients into treatment plans, emphasizing nuances between academic- and community-
based settings. The topics for discussion by the expert faculty panel will be supported by clinical cases
and enhanced by interactive polling questions and live questions submitted by attendees throughout
the presentation. Altogether, this satellite symposium will harness real-world experiences providing MM
care to deepen the impact of the education to enhance treatment selection and care coordination for
the optimal integration of novel therapies in MM across practice settings.
See more of: Friday Satellite Symposia